a protein kinase of the CDK family. Catalytic subunit of the conserved protein complex known as M-phase promoting factor (MPF), which is essential for G1/S and G2/M phase transitions. Mitotic cyclins stably associate with this protein and function as regulatory subunits. Its activity is controlled by cyclin availability and phosphorylation through the cell cycle. Activated in many cancers including colon, liver and breast. The T isoform, which lacks a regulatory region, is expressed in breast cancer. Inhibition in cancer cells may drive cells into apoptosis. May also drive cell migration. Inhibitors: BMS-265246, BMS-265246-01. 2 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: EC 188.8.131.52; EC 184.108.40.206; Cell cycle regulation; Kinase, protein; Motility/polarity/chemotaxis; Protein kinase, Ser/Thr (non-receptor); Protein kinase, CMGC; CMGC group; CDK family; CDK1 subfamily; CDK/CDK1 subfamily
Molecular Function: RNA polymerase subunit kinase activity; protein serine/threonine kinase activity; cyclin binding; protein binding; cyclin-dependent protein kinase activity; histone kinase activity; Hsp70 protein binding; ATP binding; protein kinase activity
Biological Process: regulation of Schwann cell differentiation; nerve growth factor receptor signaling pathway; activation of MAPKK activity; activation of MAPK activity; response to toxin; histone phosphorylation; regulation of embryonic development; ventricular cardiac muscle cell development; stress-activated MAPK cascade; centrosome cycle; toll-like receptor 3 signaling pathway; response to organic cyclic substance; toll-like receptor 5 signaling pathway; small GTPase mediated signal transduction; protein complex assembly; G2/M transition of mitotic cell cycle; toll-like receptor 4 signaling pathway; positive regulation of cardiac muscle cell proliferation; response to drug; mitosis; organ regeneration; fibroblast growth factor receptor signaling pathway; positive regulation of protein import into nucleus, translocation; cell aging; pronuclear fusion; toll-like receptor 2 signaling pathway; chromosome condensation; response to ethanol; cell division; response to activity; toll-like receptor 9 signaling pathway; G1/S transition of mitotic cell cycle; response to amine stimulus; negative regulation of apoptosis; positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle; axon guidance; apoptosis; mitotic nuclear envelope disassembly; positive regulation of mitotic cell cycle; toll-like receptor 10 signaling pathway; epithelial cell differentiation; anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; response to axon injury; DNA replication; epidermal growth factor receptor signaling pathway; cell migration; organelle organization and biogenesis; MyD88-independent toll-like receptor signaling pathway; MAPKKK cascade; peptidyl-threonine phosphorylation; microtubule cytoskeleton organization and biogenesis; DNA repair; MyD88-dependent toll-like receptor signaling pathway; G1/S-specific transcription in mitotic cell cycle; peptidyl-serine phosphorylation; response to cadmium ion; response to copper ion; regulation of ubiquitin-protein ligase activity during mitotic cell cycle; mitotic cell cycle G2/M transition DNA damage checkpoint; Ras protein signal transduction; toll-like receptor signaling pathway; insulin receptor signaling pathway; innate immune response; mitotic cell cycle; vascular endothelial growth factor receptor signaling pathway; positive regulation of DNA replication
Alt. Names/Synonyms: CDC2; CDC28A; CDK1; cell cycle controller CDC2; Cell division control protein 2 homolog; cell division cycle 2; cell division cycle 2, G1 to S and G2 to M; Cyclin-dependent kinase 1; DKFZp686L20222; MGC111195; p34 protein kinase; P34CDC2
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.